부산대학교 도서관

Object: The ongoing VERIFY trial is the first study that aimed to determine the durability of glycaemic control with an early combination of vildagliptin and metformin versus metformin monotherapy in drug-naïve people with T2DM. Here we report the baseline characteristics of the subjects enrolled in the ongoing VERIFY study in Korea Methods: We randomised 39 participants among the global (n = 2001) multi-ethnic population, aged 18~70 years, having glycated haemoglobin (HbA1c) levels 48~58 mmol/mol (6.5~7.5%) and body mass index (BMI) 22~40 kg/m2. Baseline data included HbA1c, fasting plasma glucose (FPG) and homeostasis model β-cell and insulin assessments for all, globally. Standardised meal-tests, insulin secretion rate relative to glucose (ISR/G), and oral glucose insulin sensitivity (OGIS) were assessed on the global level only. Results: Out of 68 screened, data were collected from the 39 eligible participants (48.7% women). Our locally assessed patients were predominantly of Asian, 94.9% race/ethnicity. The median (interquartile range; IQR) disease duration was 5.6 years months; mean (± SD. 6.31) age mean 52.8 SD 9.21 years; weight mean 70.9, SD 8.62 kg, and BMI mean 26.3 SD 2.59. 10.3% of participants were smokers. Baseline HbA1c was mean 6.9 SD 0.32mmol/mol or % and FPG was meam 7.5 SD 1.44 mmol/L. Conclusion: Our current, globally multi-ethnic, newly diagnosed VERIFY population reflects also the characteristic presence of early insulin resistance in subjects with increased demand for insulin associated with obesity in our country.